Experiment: 5JYN

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	3D TROSY HNCA	0.8 mM [U-13C; U-15N; 85%-2H] HIV-1 gp41 Transmembrane Domain, 60 mM regular 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC), 120 mM regular 1,2-Dihexanoyl-sn-Glycero-3-Phosphocholine (DHPC), 25 mM regular MES, 0.1 % regular NaN3	95% H2O/5% D2O	50 mM	6.7	1 atm	303	Bruker AVANCE II 600
2	3D TROSY HNCOCA	0.8 mM [U-13C; U-15N; 85%-2H] HIV-1 gp41 Transmembrane Domain, 60 mM regular 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC), 120 mM regular 1,2-Dihexanoyl-sn-Glycero-3-Phosphocholine (DHPC), 25 mM regular MES, 0.1 % regular NaN3	95% H2O/5% D2O	50 mM	6.7	1 atm	303	Bruker AVANCE II 600
3	3D TROSY HNCACO	0.8 mM [U-13C; U-15N; 85%-2H] HIV-1 gp41 Transmembrane Domain, 60 mM regular 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC), 120 mM regular 1,2-Dihexanoyl-sn-Glycero-3-Phosphocholine (DHPC), 25 mM regular MES, 0.1 % regular NaN3	95% H2O/5% D2O	50 mM	6.7	1 atm	303	Bruker AVANCE II 600
4	3D TROSY HNCO	0.8 mM [U-13C; U-15N; 85%-2H] HIV-1 gp41 Transmembrane Domain, 60 mM regular 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC), 120 mM regular 1,2-Dihexanoyl-sn-Glycero-3-Phosphocholine (DHPC), 25 mM regular MES, 0.1 % regular NaN3	95% H2O/5% D2O	50 mM	6.7	1 atm	303	Bruker AVANCE II 600
5	3D 15N NOESY-TROSY-HSQC	0.8 mM [U-13C; U-15N] HIV-1 gp41 Transmembrane Domain, 60 mM acyl chains 2H labeled 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC), 120 mM acyl chains 2H labeled 1,2-Dihexanoyl-sn-Glycero-3-Phosphocholine (DHPC), 25 mM regular MES, 0.1 % regular NaN3	95% H2O/5% D2O	50 mM	6.7	1 atm	303	Bruker AVANCE III 900
6	3D 13C NOESY-HSQC (Methyls)	0.8 mM [U-13C; U-15N] HIV-1 gp41 Transmembrane Domain, 60 mM acyl chains 2H labeled 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC), 120 mM acyl chains 2H labeled 1,2-Dihexanoyl-sn-Glycero-3-Phosphocholine (DHPC), 25 mM regular MES, 0.1 % regular NaN3	95% H2O/5% D2O	50 mM	6.7	1 atm	303	Bruker AVANCE III 900
7	3D 15N NOESY-TROSY-HSQC (long mixing time)	0.4 mM [U-15N; U-2H] HIV-1 gp41 Transmembrane Domain, 0.4 mM [15% 13C] HIV-1 gp41 Transmembrane Domain, 60 mM acyl chains 2H labeled 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC), 120 mM acyl chains 2H labeled 1,2-Dihexanoyl-sn-Glycero-3-Phosphocholine (DHPC), 25 mM regular MES, 0.1 % regular NaN3	95% H2O/5% D2O	50 mM	6.7	1 atm	303	Bruker AVANCE II 750
8	2D 15N TROSY-HSQC for GdDOTA titration	0.8 mM [U-13C; U-15N; 85%-2H] HIV-1 gp41 Transmembrane Domain, 60 mM regular 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC), 120 mM regular 1,2-Dihexanoyl-sn-Glycero-3-Phosphocholine (DHPC), 25 mM regular MES, 0.1 % regular NaN3	95% H2O/5% D2O	50 mM	6.7	1 atm	303	Bruker AVANCE II 600
9	3D 15N NOESY-TROSY-HSQC (short mixing time)	0.8 mM [U-15N] HIV-1 gp41 Transmembrane Domain, 60 mM acyl chains 2H labeled 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC), 120 mM acyl chains 2H labeled 1,2-Dihexanoyl-sn-Glycero-3-Phosphocholine (DHPC), 25 mM regular MES, 0.1 % regular NaN3	95% H2O/5% D2O	50 mM	6.7	1 atm	303	Bruker AVANCE II 600

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE II	600
2	Bruker	AVANCE II	750
3	Bruker	AVANCE III	900

NMR Refinement
Method	Details	Software
simulated annealing		XPLOR-NIH

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	150
Conformers Submitted Total Number	15
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
2	structure calculation	XPLOR-NIH	2.42	G. Marius Clore , Guillermo Bermejo, , John Kuszewski, Charles D. Schwieters, and Nico Tjandra
3	chemical shift assignment	CcpNMR		CCPN
5	processing	NMRPipe		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
6	data analysis	XEASY		Bartels et al.
7	data analysis	TALOS		Cornilescu, Delaglio and Bax
1	refinement	XPLOR-NIH	2.42	G. Marius Clore , Guillermo Bermejo, , John Kuszewski, Charles D. Schwieters, and Nico Tjandra

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.